´ÙÁ¦³»¼º°áÇÙ±Õ¿¡¼ À¯ÀüÀÚ º¯À̺м®À» ÀÌ¿ëÇÑ Äû³î·Ð ³»¼º°ËÃâÀÇ À¯¿ë¼º Æò°¡
Molecular Detection of Fluoroquinolone Resistance in Multidrug-Resistant Mycobacterium tuberculosis Isolates
´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸÁö 2014³â 17±Ç 3È£ p.80 ~ p.85
±èâ±â(Kim Chang-Ki) - ´ëÇѰáÇÙÇùȸ °áÇÙ¿¬±¸¿ø
À̺´¼ö(Lee Byung-Soo) - ´ëÇѰáÇÙÇùȸ °áÇÙ¿¬±¸¿ø
ÃÖ¸íÁØ(Choi Myung-Joon) - ´ëÇѰáÇÙÇùȸ °áÇÙ¿¬±¸¿ø
±èÈñÁø(Kim Hee-Jin) - ´ëÇѰáÇÙÇùȸ °áÇÙ¿¬±¸¿ø
ÀÌ°æ¿ø(Lee Kyung-Won) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
Abstract
¹è°æ: Fluoroquinolone (FQ)´Â ´ÙÁ¦³»¼º°áÇÙ Ä¡·á¿¡ ÀÖ¾î¼ Áß¿äÇÑ ¾àÁ¦ÀÌ´Ù. ±Ù·¡ ±¤¹üÀ§ÇÑ FQÀÇ »ç¿ëÀ¸·Î ÀÎÇØ °áÇÙ±Õ¿¡¼ÀÇ ³»¼ºÀÌ Áõ°¡Çϰí ÀÖ¾î ½Å¼ÓÇϰí Á¤È®ÇÑ FQ ³»¼º°Ë»çÀÇ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ´Ù. º» ¿¬±¸¿¡¼´Â ºÐÀÚ»ý¹°ÇÐÀû ¹æ¹ý
À» ÀÌ¿ëÇÑ °áÇÙ±Õ FQ ³»¼º°ËÃâÀÇ À¯¿ë¼ºÀ» Æò°¡ÇϰíÀÚ ÇÏ¿´´Ù.
¹æ¹ý: 2009³â 1¿ùºÎÅÍ 10¿ù±îÁö ¼öÁýµÈ 95°³ÀÇ ´ÙÁ¦³»¼º°áÇÙ±ÕÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Ofloxacin (OFL), levofloxacin ±×¸®°í moxifloxacin¿¡ ´ëÇÑ °¨¼ö¼ºÀº Lowenstein-Jensen¹èÁö Àý´ë³óµµ¹ýÀ¸·Î ½ÃÇèÇÏ¿´°í ³»¼º±âÁØ ³óµµ´Â µ¿ÀÏÇÏ°Ô 2.0 ¥ìg/mL
À» ÀÌ¿ëÇÏ¿´´Ù. ¾×ü¹èÁö ¹Ì·®Èñ¼®¹ýÀ¸·Î ¼¼ ¾àÁ¦ÀÇ ÃÖ¼Ò¾ïÁ¦³óµµ¸¦ ½ÃÇèÇÏ¿´À¸¸ç gyrA¿Í gyrB À¯ÀüÀÚÀÇ quinolone-resistance
determining region (QRDR) ¿°±â¼¿À» ºÐ¼®ÇÏ¿´´Ù.
°á°ú: 95ÁÖ Áß¿¡¼ 79ÁÖ°¡ Çϳª ÀÌ»óÀÇ FQ¿¡ ³»¼ºÀ̾ú°í, ÀÌÁß 71 (89.9%)ÁÖ¿¡¼ gyrA ȤÀº gyrBÀÇ QRDR¿¡ º¯À̰¡ ¹ß°ßµÇ¾ú´Ù. ¹Ý¸é FQ¿¡ °¨¼ö¼ºÀÎ ±ÕÁÖ¿¡¼´Â º¯À̰¡ °üÂûµÇÁö ¾Ê¾Ò´Ù. gyrA À¯ÀüÀÚÀÇ codon 94 À§Ä¡¿¡ º¯À̰¡ °¡Àå ÈçÇÏ¿´°í
2ÁÖ¿¡¼ gyrB º¯À̸¸ °üÂûµÇ¾ú´Ù. gyrA À¯ÀüÀÚ º¯À̰¡ È®ÀÎµÈ ±ÕÁÖ¿¡ ´ëÇÑ OFL ÃÖ¼Ò¾ïÁ¦³óµµ´Â 1-32 ¥ìg/mLÀ̾úÀ¸³ª,
FQ °¨¼ö¼º ±ÕÁÖ¿¡ ´ëÇÑ OFL ÃÖ¼Ò¾ïÁ¦³óµµ´Â ¡Â0.06-0.5 ¥ìg/mL·Î Â÷À̰¡ ÀÖ¾ú´Ù.
°á·Ð: gyrA¿Í gyrB QRDR º¯À̺м®ÀÇ FQ ³»¼º°ËÃ⠹ਵµ¿Í ƯÀ̵µ°¡ 89.9%¿Í 100%·Î ¿ì¼öÇÏ¿© ´ÙÁ¦³»¼º°áÇÙ±Õ¿¡¼
½Å¼ÓÇÑ FQ ³»¼º°ËÃâ¿¡ À¯¿ëÇÒ °ÍÀ¸·Î ÆÇ´ÜµÇ¾ú´Ù.
Background: Fluoroquinolones (FQs) are important drugs for treating multidrug-resistant tuberculosis(MDR-TB). However, due to widespread use of FQs, the resistance rates to FQs have been increasing among Mycobacterium tuberculosis. Rapid and reliable FQ drug susceptibility testing (DST) is crucial for successful treatment of MDR-TB. In this study, the feasibility of molecular detection of FQ resistance
was evaluated.
Methods: A total of 95 MDR-TB isolates were collected from Jan through Oct 2009 at the Korean Institute of Tuberculosis. DST for ofloxacin (OFL), levofloxacin, and moxifloxacin was performed using the Lowenstein-Jensen media absolute concentration method. Minimum inhibitory concentrations (MIC) of these were determined using the broth microdilution method. DNA was extracted from cultured isolates using bead beating method. The quinolone resistance-determining region (QRDR) of gyrA and gyrB were amplified and those sequences were analyzed.
Results: Of 95 isolates, 79 were resistant to at least one of FQs. Of these, 71 (89.9%) harbored mutation in the QRDR of gyrA or gyrB. None of FQ susceptible strains possessed any mutation in gyrA or gyrB. Mutations in codon 94 of gyrA were most common; only two isolates had mutation in only the gyrB gene. OFL MICs for isolates with gyrA mutation ranged from 1 to 32 ¥ìg/mL, but FQ susceptible isolates showed MICs ranging from ¡Â0.06 to 0.5 ¥ìg/mL.
Conclusion: Mutation analysis of QRDR of gyrA and gyrB showed 89.9% sensitivity and 100% specificity for detecting FQ resistance in MDR-TB. Therefore, molecular DST can be useful for rapid detection of FQ resistance in MDR-TB.
Ű¿öµå
Fluoroquinolone, gyrA, gyrB, Multidrugresistant tuberculosis
KMID :
0829320140170030080
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)